Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Telithromycin. Aventis Pharma.

A P Johnson1

  • 1Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, London, UK. ajohnson@phls.nhs.uk

Current Opinion in Investigational Drugs (London, England : 2000)
|March 15, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Validation and Reliability of the Dyslexia Adult Checklist in Screening for Dyslexia.

Dyslexia (Chichester, England)·2024
Same author

Intermittent point prevalence surveys on healthcare-associated infections, 2011 and 2016, in England: what are the surveillance and intervention priorities?

The Journal of hospital infection·2023
Same author

Hot for Robots! Sexual Arousal Increases Willingness to Have Sex with Robots.

Journal of sex research·2022
Same author

Assessing the added value of group B Streptococcus maternal immunisation in preventing maternal infection and fetal harm: population surveillance study.

BJOG : an international journal of obstetrics and gynaecology·2021
Same author

Surveillance of bloodstream infections in intensive care units in England, May 2016-April 2017: epidemiology and ecology.

The Journal of hospital infection·2020
Same author

Music predictability and liking enhance pupil dilation and promote motor learning in non-musicians.

Scientific reports·2019
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Telithromycin, a novel ketolide antibiotic, is approved for respiratory tract infections. Regulatory reviews indicated potential cardiovascular and liver risks for some uses, impacting its market approval and sales forecasts.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Drug Development

Background:

  • Telithromycin (HMR-3647; Ketek) is a ketolide antibiotic, a clarithromycin derivative.
  • It targets a broad spectrum of bacteria, including Gram-positive cocci, Gram-negative cocci, Haemophilus influenzae, Streptococcus pneumoniae, Moraxella catarrhalis, intracellular pathogens, atypical microorganisms, toxoplasma, and anaerobic bacteria.

Purpose of the Study:

  • To detail the regulatory status and market launch of telithromycin for respiratory tract infections.
  • To summarize the findings of regulatory reviews regarding efficacy and safety for various indications.

Main Methods:

  • Review of regulatory filings and approvals in the US and EU.
  • Analysis of advisory committee recommendations and company communications regarding product launch and indications.

Related Experiment Videos

Main Results:

  • Telithromycin received marketing authorization in the EU for community-acquired respiratory tract infections in July 2001 and launched in Germany in October 2001.
  • The FDA Anti-Infective Drugs Advisory Committee recommended approval for community-acquired pneumonia (CAP) but not for acute sinusitis, acute exacerbations of chronic bronchitis, or tonsillitis/pharyngitis due to safety concerns.
  • An approvable letter was received for CAP, acute bacterial exacerbations of chronic bronchitis, and acute bacterial sinusitis, but not for tonsillitis/pharyngitis.

Conclusions:

  • Telithromycin gained approval for specific respiratory tract infections, with some indications facing regulatory hurdles due to safety concerns.
  • Sales forecasts varied significantly among financial analysts, reflecting uncertainty about market penetration and regulatory outcomes.